Brief: Spexis: Total Loss Of CHF 3.9 Mln In H1 2023

Spexis AG

29/09/2023 06:37

Sept 29 (Reuters) - Spexis Ag  SPEXN.S :
    * SPEXIS PROVIDES BUSINESS UPDATE AND ANNOUNCES FINANCIAL
RESULTS
FOR THE FIRST HALF OF 2023
    * BALIXAFORTIDE, A POTENT CXCR4 INHIBITOR, TO BE EVALUATED
FOR
TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
    * PEXIS CLOSED CAPITAL COMMITMENTS TOTALING USD $7.5 MILLION
SUPPORTING PHASE 3 COLIFIN® PROGRAM IN CYSTIC FIBROSIS (CF)
INFECTIONS
    * COPILOT STUDY EXPECTED TO INITIATE IN Q4 2023
    * ENGAGED MAXIM GROUP LLC AS M&A ADVISOR TO EVALUATE
STRATEGIC
TRANSACTIONS OF WHICH SPEXIS WOULD BE SURVIVING COMPANY
    * IN FIRST HALF OF 2023, SPEXIS' TOTAL LOSS WAS CHF 3.9
MILLION

Source text for Eikon:  ID:nEQ47K5k1a 
Further company coverage:  SPEXN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))